Special Interests:Single cell genomics and translational genomics Genetic epidemiolody and hereditary cancers Ovarian cancer Biomarker development
About Kevin Hasegawa Eng
Dr. Eng is a cancer geneticist and statistician with broad expertise in immunology, genetics, epidemiology and informatics. His research group combines a traditional bench laboratory and a computational group to execute translational studies in ovarian and prostate cancers. Dr. Eng earned his PhD and MS from the University of Wisconsin-Madison and ScB from Brown University. Dr. Eng studied statistical genomics, bioinformatics and ovarian cancer during his postdoctoral training at Wisconsin. Combining genomics, informatics and immunology, Dr. Eng has recently received an NIH career award (K award) developed through awards from the ovarian cancer SPORE and the Roswell Park Alliance Foundation.
Roswell Park Comprehensive Cancer Center
- Associate Professor of Oncology
- Department of Biostatistics and Bioinformatics (Primary)
- Department of Cancer Genetics and Genomics (Secondary Appointment)
Education and Training:
- 2011 - PhD - University of Wisconsin-Madison
- 2009 - MS - University of Wisconsin-Madison
Cancer is a disease of the genome and researchers now appreciate that tumors evolve at a genomic scale before, during and after cancer therapy. These scales involve the interaction between DNA sequences and their regulation as well as the highly complex multivariate transcriptomic space. Research in the Eng laboratory is motivated by studying the forces that shape variation and constraint in the tumor. What changes can be tolerated in a genome and what changes are absolutely critical to create a tumor? How complicated can it really be – what is the minimum amount of genomic information required to characterize a tumor? Importantly, what concepts can be translated into the clinic to strategically treat patients? We employ concepts and tools from genomics, systems biology, and big-data computational biology to tackle these questions. Our work uses human samples and mouse and human model systems and involves functional, therapeutic and animal studies.
X-linked Ovarian Cancer
- Etter, J.L., Moysich, K., Kohli, S., Lele, S., Odunsi, K. & Eng, K.H. (2020). Transmission of X-linked Ovarian Cancer: Characterization and Implications Affiliations expand. Diagnostics (Basel), 10(2), 90. PMCID: PMC7167857.
- Etter, J.L., Eng, K.H., Cannioto, R., Kaur, J., Almohanna, H., Alqassim, E., Szender, J.B., Joseph, J.M., Lele, S., Odunsi, K. Moysich, K.B. (2018). Hereditary association between testicular cancer and familial ovarian cancer: A Familial Ovarian Cancer Registry study. Cancer Epidemiology, 53, 184-186. PMCID: PMC6713187.
- Eng, K.H., Szender, J.B., Etter, J.L., Kaur, J., Poblete, S., Huang, R,Y., Zhu, Q., Grzesik, K.A., Battaglia, S., Cannioto, R., Krolewski, J,J., Zsiros, E., Frederick, P.J., Lele, S.B., Moysich, K.B. & Odunsi, K.O. (2018). Paternal lineage early onset hereditary ovarian cancers: A Familial Ovarian Cancer Registry study. PLoS Genetetics, 14(2), e1007194. PMCID: PMC5813894.
Ovarian Cancer Ascites
- Szender, J.B., Emmons, T., Belliotti, S., Dickson, D., Khan, A., Morrell, K., Nazmul Khan, A.N.M., Singel, K.L., Mayor, P.C., Moysich, K.B., Odunsi, K., Segal, B.H. & Eng, K.H. (2017). Impact of ascites volume on clinical outcomes in ovarian cancer: A cohort study. Gynecologic Oncology, 146(3):491-497. PMCID: PMC5568462
- Seagle, B.L.L., Eng, K.H., Yeh, J.Y., Dandapani, M., Schiller, E., Samuelson, R., Odunsi, K. & Shahabi, S.(2016). Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Scientific Reports, 6: 21591. PMCID: PMC4756718
- Starbuck, K.D., Szender, J.B., Duncan, W.D., Morrell, K., Etter, J.L., Zsiros, E., Odunsi, K., Moysich, K. & Eng, K.H. (2018). Prognostic impact of adjuvant chemotherapy treatment intensity for ovarian cancer. PLoS One, 13(11):e0206913. PMCID: PMC6231633
- Eng, K.H., Morrell, K., Starbuck, K., Spring-Robinson, C., Khan, A., Cleason, D., Akman, L., Zsiros, E., Odunsi, K. & Szender, J.B. (2017). Prognostic value of miliary versus non-miliary sub-staging in advanced ovarian cancer. Gynecologic Oncology, 146(1):52-57. PMCID: PMC5592637
- Szender, J.B., Eng, K.H., Matsuzaki, J., Miliotto, A., Gnjatic, S., Tsuji, T. & Odunsi, K. (2016). HLA superfamily assignment is a predictor of immune response to cancer testis antigens and survival in ovarian cancer. Gynecologic Oncology, 142(1):158-162. PMCID: PMC4917411
- Zhang, W., Barger, C.J., Eng, K.H., Klinkebiel, D., Link, P.A., Omilian, A., Bshara, W., Odunsi, K. & Karpf, A.R. (2016). PRAME expression and promoter hypomethylation in epithelial ovarian cancer. Oncotarget, 7(29):45352-45369. PMCID: PMC5216727
- Eng, K.H., Weir, I., Tsuji, T. & Odunsi, K. (2015). Immuno-stimultory/regulatory gene expression patterns in advanced ovarian cancer. Genes Cancer, 6(9-10):399-407. PMCID: PMC4633167
- Szender, J.B., Papanicolau-Sengos, A., Eng, K.H., Miliotto, A.J., Lugade, A.A., Gnjatic, S., Matsuzaki, J., Morrison, C.D. & Odunsi, K. (2017). NY-ESO-1 expression predicts an aggressive phenotype of ovarian cancer. Gynecologic Oncology, 145(3):420-425. PMCID: PMC5497581
- Daudi, S., Eng, K.H., Mhawech-Fauceglia, P., Morrison, C., Miliotto, A., Beck, A., Matsuzaki, J., Tsuji, T., Groman, A., Gnjatic, S., Spagnoli, G., Lele, S. & Odunsi, K. (2014). Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One, 9(8):e104099. PMCID: PMC4125181
- Daudi, S., Eng, K.H., Mhawech-Fauceglia, P., Morrison, C., Miliotto, A., Beck, A., Matsuzaki, J., Tsuji, T., Groman, A., Gnjatic, S., Spagnoli, G., Lele, S. & Odunsi, K. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS ONE 2014; 9(8):e104099. PMCID: PMC4125181
- Eng, K.H. & Tsuji, T. Differential antigen expression profile predicts immunoreactive subset of advanced ovarian cancers. PLoS ONE 2014; 9(11):e111586. PMCID: PMC4224408
- Eng, K.H. & Ruggeri, C. Connecting prognostic ligand receptor signaling loops in advanced ovarian cancer. PLoS ONE 2014; 9(9):e107193. PMCID: PMC4171104
- Eng, K.H. Randomized reverse marker strategy design for prospective biomarker validation. Statistics in Medicine 2014; 33(18):3089-3099. PMCID: PMC4107176
- Eng, K.H., Wang, S., Bradley, W.H., Rader, J.S. & Kendziorski, C. Pathway index models for construction of patient-specific risk profiles. Statistics in Medicine 2013; 32(9):1524-1535. PMCID: PMC3593986